Author Archives: admin


US regulations for regenerative medicine advanced therapies – Regulatory Focus

This article examines US regulations and guidance documents for regenerative medicine advanced therapies (RMATs). The author describes the field of regenerative medicine, noting that it is expanding at an accelerated pace, and outlines some of the common terms associated with it. He also addresses the application process for these therapies, accelerated regulatory pathways, market access, and the outlook for RMATs. The author cautions that, as exciting as these therapies are, they require a rigorous and carefully planned approach to ensure a seamless progression to regulatory approval and commercial success. Introduction Regenerative medicine is a rapidly expanding field, offering the potential to treat serious and life-threatening conditions by replacing, or regenerating, human cells, tissues, or organs that have been damaged by disease, trauma, or congenital defects.1 With more than 200 investigational new drug (IND) applications anticipated by the US Food and Drug Administration (FDA) in 2020,2 regenerative medicine should yield many new therapies with enormous benefits to patients, especially those with unmet medical needs. Navigating the complex regulatory environment of regenerative medicine requires companies to engage with the FDA early and often throughout the drug development process to identify and overcome potential obstacles to approval. Many of these therapies are developed by scientific institutions and medical research groups with limited inhouse regulatory resources, so it is advisable to seek external regulatory support early in the planning process. Regenerative medicines defined Regenerative medicines, as defined by the FDA, include cell therapies (non- and genetically modified), therapeutic tissue-engineering products, human cell and tissue products, and combination products using these biologic components, which lead to a sustained effect on cells and tissues. In addition, a combination product (biologic device, biologic drug, or biologic device-drug) can be eligible for regenerative medicine advanced therapy (RMAT) designation when the biological product constituent part is a regenerative medicine therapy and provides the greatest contribution to the overall intended therapeutic effects of the combination product (i.e., the primary mode of action of the combination product is conveyed by the biological product constituent part). In January 2020, the FDA released six final guidances on gene therapy manufacturing and clinical development of products and a draft guidance.3 The FDAs policy to advance the development of safe and effective cell and gene therapies can be found here.4 This article explains some of the terminology and covers the key US regulations and guidance documents. Discussions of a select number of these documents will be published in separate articles in Regulatory Focus. Terminology Cellular & gene therapy products5 Cellular therapy products include cellular immunotherapies, cancer vaccines, and other types of autologous and allogeneic cells, including hematopoietic stem cells and adult and embryonic stem cells, for certain therapeutic indications. Human gene therapy seeks to modify or manipulate the expression of a gene or to alter the biological properties of living cells for therapeutic use. The FDAs Center for Biologics Evaluation and Research (CBER) has approved both cellular and gene therapy products.5 Gene therapy6 Gene therapy is a technique that modifies a persons faulty genes treat or cure disease and is most often applied to cancer, genetic diseases and infectious diseases. Gene therapies can work by several mechanisms:

The following figureshows CBERs organisation for pre and postmarket regulation35

Market access and outlook As of May 2019, the FDA had granted 34 products FDA regenerative medicine advanced therapy designations.36 In all, 68 of the 100 designation applications were cell therapy products, 20 of the 34 RMAT granted products have orphan product designation, and 11 of the 34 have fast track designation. While the promise of regenerative medicines to cure disease is driving the field forward at an accelerated pace, developing these therapies require a rigorous and carefully planned approach to ensure a seamless progression to regulatory approval and commercial success. Abbreviations ANDA, abbreviated new drug application; CBER, Center for Biologics Evaluation and Research; FDA, Food and Drug Administration; HCT/P, human cell, tissue, and cellular and tissue-based product; IND, investigational new drug; PDUFA, Prescription Drug User Fee Act; rDNA, ribosomal DNA; RMAT, regenerative medicine advanced therapy. References All references were accessed 23 July 2020.

Read the original here:
US regulations for regenerative medicine advanced therapies - Regulatory Focus

This is What He and His Family Are Working Towards- Former Ferrari Head Todt Reveals He Saw Michael Schumacher Last Week – Essentially Sports

Gauging the progress made by Formula 1 legend, Michael Schumacher, as far as his health is concerned, often seems like a losing battle. The Schumacher family has mostly been very private about the 7-time world champions condition and health ever since he suffered a horrific skiing accident, about 6 and a half years ago.

Last month, reports indicated that the F1 legends stem cell surgery was put on hold due to the pandemic. Since then, there has been no update about Schumis health. Until now.

Former Ferrari CEO Jean Todt, who is a rather close acquaintance to Schumacher, gives fans some reason for optimism.

According to Dailymail, the former CEO of Ferrari said, I saw Michael last week. He is fighting. I hope that the world will be able to see him again. This is what he and his family are working towards.

It may not be a lot in terms of an update, but well savor whatever information we can get about the F1 legend. We wish him a speedy recovery and hope to see him soon enough.

Todt obviously shares a very special connection with Schumi. Todt occupied the role of the Team Principal at Scuderia Ferrari, and he was responsible for bringing Michael in to Ferrari in 1996.

Schumacher, at the time, had won back-to-back world titles with Benetton.

The duo of Todt and Schumacher saw the Maranello-based outfit through their most successful years in the sport of Formula 1.

For five consecutive seasons, Schumacher dominated F1 and won back-to-back world titles. His brilliance also led The Prancing Horse to win 5 back-to-back Constructors championship titles as well.

Thereafter, Todt was promoted to the role of CEO of the Ferrari brand for four years (2004-08). Now he is part of the UN Secretary-Generals special envoy for road safety.

As for Michael, he continued at Ferrari for two more seasons, finishing 3rd and 2nd respectively. After that, the German driver retired from F1 for 3 years.

But the love for the sport couldnt keep him out for long, and he was back for a second stint with Mercedes.

However, that move didnt go to plan and Schumi retired for a second time after the 2013 season. This time for good.

See the original post here:
This is What He and His Family Are Working Towards- Former Ferrari Head Todt Reveals He Saw Michael Schumacher Last Week - Essentially Sports

Covid-19 Updates : Exosome Therapeutic Market 2020-2026 Analysis, Insights, Trends, Key Players, Drivers and Forecast | Leading Players evox…

Data Bridge Market Research (DBMR) has published a latest market research report on Global Exosome Therapeutic Market . The global report is prepared in collaboration with the leading industry experts & dedicated research analyst team to provide an enterprise with in-depth market insights & help them to take crucial business decisions. This report covers current market trends, opportunities, challenges & detailed competitive analysis of the industry players in the market.

Get Sample PDF (including COVID19 Impact Analysis) of Market Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-exosome-therapeutic-market&rp

The Global Exosome Therapeutic Market analysis report is a detailed study of market size, share and dynamics covered in 350 pages & is an illustrative sample demonstrating market trends. This is a latest research report , covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life worldwide. This has brought along with several changes in market conditions . The rapidly changing market scenario & initial and future assessment of the impact is covered in the report. It covers the entire market with an in-depth study on revenue growth & profitability. The report also delivers on key players along with strategic standpoint pertaining to price & promotion.

Market Analysis and Insights:Global Exosome Therapeutic Market

Exosome therapeutic market is expected to gain market growth in the forecast period of 2019 to 2026. Data Bridge Market Research analyses that the market is growing with a CAGR of 21.9% in the forecast period of 2019 to 2026 and expected to reach USD 31,691.52 million by 2026 from USD 6,500.00 million in 2018. Increasing prevalence of lyme disease, chronic inflammation, autoimmune disease and other chronic degenerative diseases are the factors for the market growth.

The major players covered in the Exosome Therapeutic Market report are evox THERAPEUTICS, EXOCOBIO, Exopharm, AEGLE Therapeutics, United Therapeutics Corporation, Codiak BioSciences, Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, ReNeuron Group plc, Capricor Therapeutics, Avalon Globocare Corp., CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC., Stem Cells Group among other players domestic and global. Exosome therapeutic market share data is available for Global, North America, Europe, Asia-Pacific, and Latin America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Get Full TOC, Tables and Figures of Market Report @https://www.databridgemarketresearch.com/toc/?dbmr=global-exosome-therapeutic-market&rp

Exosomes are used to transfer RNA, DNA, and proteins to other cells in the body by making alteration in the function of the target cells. Increasing research activities in exosome therapeutic is augmenting the market growth as demand for exosome therapeutic has increased among healthcare professionals.

Increased number of exosome therapeutics as compared to the past few years will accelerate the market growth. Companies are receiving funding for exosome therapeutic research and clinical trials. For instance, In September 2018, EXOCOBIO has raised USD 27 million in its series B funding. The company has raised USD 46 million as series a funding in April 2017. The series B funding will help the company to set up GMP-compliant exosome industrial facilities to enhance production of exosomes to commercialize in cosmetics and pharmaceutical industry.

Increasing demand for anti-aging therapies will also drive the market. Unmet medical needs such as very few therapeutic are approved by the regulatory authority for the treatment in comparison to the demand in global exosome therapeutics market will hamper the market growth market. Availability of various exosome isolation and purification techniques is further creates new opportunities for exosome therapeutics as they will help company in isolation and purification of exosomes from dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, and urine and from others sources. Such policies support exosome therapeutic market growth in the forecast period to 2019-2026.

This exosome therapeutic market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for anAnalyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Exosome Therapeutic Market Scope and Market Size

Global exosome therapeutic market is segmented of the basis of type, source, therapy, transporting capacity, application, route of administration and end user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Based on type, the market is segmented into natural exosomes and hybrid exosomes. Natural exosomes are dominating in the market because natural exosomes are used in various biological and pathological processes as well as natural exosomes has many advantages such as good biocompatibility and reduced clearance rate compare than hybrid exosomes.

Exosome is an extracellular vesicle which is released from cells, particularly from stem cells. Exosome functions as vehicle for particular proteins and genetic information and other cells. Exosome plays a vital role in the rejuvenation and communication of all the cells in our body while not themselves being cells at all. Research has projected that communication between cells is significant in maintenance of healthy cellular terrain. Chronic disease, age, genetic disorders and environmental factors can affect stem cells communication with other cells and can lead to distribution in the healing process. The growth of the global exosome therapeutic market reflects global and country-wide increase in prevalence of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases, along with increasing demand for anti-aging therapies. Additionally major factors expected to contribute in growth of the global exosome therapeutic market in future are emerging therapeutic value of exosome, availability of various exosome isolation and purification techniques, technological advancements in exosome and rising healthcare infrastructure.

Rising demand of exosome therapeutic across the globe as exosome therapeutic is expected to be one of the most prominent therapies for autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases treatment, according to clinical researches exosomes help to processes regulation within the body during treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases. This factor has increased the research activities in exosome therapeutic development around the world for exosome therapeutic. Hence, this factor is leading the clinician and researches to shift towards exosome therapeutic. In the current scenario the exosome therapeutic are highly used in treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases and as anti-aging therapy as it Exosomes has proliferation of fibroblast cells which is significant in maintenance of skin elasticity and strength.

Based on source, the market is segmented into dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, urine and others. Mesenchymal stem cells are dominating in the market because mesenchymal stem cells (MSCs) are self-renewable, multipotent, easily manageable and customarily stretchy in vitro with exceptional genomic stability. Mesenchymal stem cells have a high capacity for genetic manipulation in vitro and also have good potential to produce. It is widely used in treatment of inflammatory and degenerative disease offspring cells encompassing the transgene after transplantation.

Based on therapy, the market is segmented into immunotherapy, gene therapy and chemotherapy. Chemotherapy is dominating in the market because chemotherapy is basically used in treatment of cancer which is major public health issues. The multidrug resistance (MDR) proteins and various tumors associated exosomes such as miRNA and IncRNA are include in in chemotherapy associated resistance.

Based on transporting capacity, the market is segmented into bio macromolecules and small molecules. Bio macromolecules are dominating in the market because bio macromolecules transmit particular biomolecular information and are basically investigated for their delicate properties such as biomarker source and delivery system.

Based on application, the market is segmented into oncology, neurology, metabolic disorders, cardiac disorders, blood disorders, inflammatory disorders, gynecology disorders, organ transplantation and others. Oncology segment is dominating in the market due to rising incidence of various cancers such as lung cancer, breast cancer, leukemia, skin cancer, lymphoma. As per the National Cancer Institute, in 2018 around 1,735,350 new cases of cancer was diagnosed in the U.S. As per the American Cancer Society Inc in 2019 approximately 268,600 new cases of breast cancer diagnosed in the U.S.

Based on route of administration, the market is segmented into oral and parenteral. Parenteral route is dominating in the market because it provides low drug concentration, free from first fast metabolism, low toxicity as compared to oral route as well as it is suitable in unconscious patients, complicated to swallow drug etc.

The exosome therapeutic market, by end user, is segmented into hospitals, diagnostic centers and research & academic institutes. Hospitals are dominating in the market because hospitals provide better treatment facilities and skilled staff as well as treatment available at affordable cost in government hospitals.

Exosome therapeutic Market Country Level Analysis

The global exosome therapeutic market is analysed and market size information is provided by country by type, source, therapy, transporting capacity, application, route of administration and end user as referenced above.

The countries covered in the exosome therapeutic market report are U.S. and Mexico in North America, Turkey in Europe, South Korea, Australia, Hong Kong in the Asia-Pacific, Argentina, Colombia, Peru, Chile, Ecuador, Venezuela, Panama, Dominican Republic, El Salvador, Paraguay, Costa Rica, Puerto Rico, Nicaragua, Uruguay as part of Latin America.

Country Level Analysis, By Type

North America dominates the exosome therapeutic market as the U.S. is leader in exosome therapeutic manufacturing as well as research activities required for exosome therapeutics. At present time Stem Cells Group holding shares around 60.00%. In addition global exosomes therapeutics manufacturers like EXOCOBIO, evox THERAPEUTICS and others are intensifying their efforts in China. The Europe region is expected to grow with the highest growth rate in the forecast period of 2019 to 2026 because of increasing research activities in exosome therapeutic by population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Huge Investment by Automakers for Exosome Therapeutics and New Technology Penetration

Global exosome therapeutic market also provides you with detailed market analysis for every country growth in pharma industry with exosome therapeutic sales, impact of technological development in exosome therapeutic and changes in regulatory scenarios with their support for the exosome therapeutic market. The data is available for historic period 2010 to 2017.

Competitive Landscape and Exosome Therapeutic Market Share Analysis

Global exosome therapeutic market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, concept cars, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companys focus related to global exosome therapeutic market.

Many joint ventures and developments are also initiated by the companies worldwide which are also accelerating the global exosome therapeutic market.

For instance,

Partnership, joint ventures and other strategies enhances the company market share with increased coverage and presence. It also provides the benefit for organisation to improve their offering for exosome therapeutics through expanded model range.

Customization Available:Global Exosome Therapeutic Market

Data Bridge Market Researchis a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-exosome-therapeutic-market&rp

About Data Bridge Market Research :

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us :

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Mail:Corporatesales@databridgemarketresearch.com

Original post:
Covid-19 Updates : Exosome Therapeutic Market 2020-2026 Analysis, Insights, Trends, Key Players, Drivers and Forecast | Leading Players evox...

First Edition: July 24, 2020 – Kaiser Health News

Today's early morning highlights from the major news organizations.

Kaiser Health News and USA Today: Less-Lethal Weapons Blind, Maim And Kill. Victims Say Enough Is Enough. Theres a gap in Scott Olsens memory for the night of Oct. 25, 2011. The Iraq War vet remembers leaving his tech job in the San Francisco Bay Area and taking a BART train to join an Occupy Oakland protest against economic and social inequality. He remembers standing near protesters who faced off with Oakland police officers bristling with riot gear. He remembers being carried away by other protesters. But not the moment when a bean bag round fired from an officers 12-gauge shotgun crashed into the left side of his head, fracturing his skull and inflicting a near-fatal brain injury that forced him to relearn how to talk. (Slack, Wagner, Hancock, McCoy, 7/24)

Kaiser Health News: Technology Divide Between Senior Haves And Have-Nots Roils Pandemic Response Family gatherings on Zoom and FaceTime. Online orders from grocery stores and pharmacies. Telehealth appointments with physicians. These have been lifesavers for many older adults staying at home during the coronavirus pandemic. But an unprecedented shift to virtual interactions has a downside: Large numbers of seniors are unable to participate. (Graham, 7/24)

Kaiser Health News and PolitiFact: With DACA Ruling, Did Supreme Court Grant Trump New Powers To Reshape Health Care? President Donald Trump came into office vowing to repeal and replace Obamacare. While he successfully neutralized the health care laws requirement that everyone carry insurance, the lawremains in effect. When Fox News host Chris Wallace noted that Trump has yet to put forward a replacement plan, Trump told him to stay tuned. Were signing a health care plan within two weeks, a full and complete health care plan that the Supreme Court decision on DACA gave me the right to do, Trump saidJuly 19 on Fox News Sunday. (Greenberg, 7/24)

Kaiser Health News: Lost On The Frontline A lab assistant who spoke out about employee safety. A disease intervention specialist who hoped to follow her mother into nursing. A father of three who juggled jobs at three nursing homes. These are some of the people just added to Lost on the Frontline, a special series from The Guardian and KHN that profiles health care workers who died of COVID-19. (7/24)

The Wall Street Journal: U.S. Coronavirus Deaths Surpass 144,000 The U.S. death toll from the coronavirus pandemic rose above 144,000 as several states reported record single-day fatalities. The U.S. reported more than 68,000 new cases Thursday, slightly lower than the previous days tally. The nation accounts for more than a quarter of the more than 15.5 million coronavirus cases world-wide, according to data compiled by Johns Hopkins University. Higher case counts in the U.S. are partly attributable to expanded testing across the country, while a patchwork of rules and regulations has contributed to a resurgence of new cases. (Hall, 7/24)

CIDRAP: Just A Few Nations Driving Much Of World's COVID-19 Surge The global surge in COVID-19 cases is mainly driven by intense transmission in a relatively few countries, the head of the World Health Organization (WHO) said today, with South Africa now among the five hardest-hit countries. The global total today is at 15,348,877 cases, and 626,190 people have died from their illnesses, according to the Johns Hopkins online dashboard. (Schnirring, 7/23)

The New York Times: Its Emotional Whiplash: California Is Once Again At The Center Of The Virus Crisis When everything shut down in March as the coronavirus took off in California, Canters Deli, a mainstay in the Fairfax District of Los Angeles, laid off dozens of employees. A few months later, it called them back to work. By then, the state appeared to have emerged from the initial virus crisis in much better shape than other parts of the country. But now Californias caseload is exploding, with rising deaths and hospitalizations. As quickly as things had opened up, they have shut down again. (Arango and Mervosh, 7/23)

The Hill: California, Florida Report Record Numbers Of Daily Deaths California and Florida reported record numbers of daily coronavirus fatalities Thursday, as the total number of infections in the U.S. surpassed 4 million. California's 157 deaths on Wednesday continued aweek of coronavirus records in the state that had once been considered a COVID success story. Gov. Gavin Newsom (D) on Wednesday said 12,807 new coronavirus infections had been reported statewide in 24 hours, a record high.(Weixel, 7/23)

Politico: Spiking Or Plateauing? Covid-19 Case Counts Spur Debate A monthlong resurgence in Covid-19 cases appears to be hitting a peak, but a new assessment of the coronavirus trajectory is fueling conflicting interpretations about whether the worst is over. Slowing caseloads in Florida and Arizona have fanned a narrative that the worst of the disease spread is cresting in some of the nations worst hot spots repeating a pattern seen in early June. But public health experts on Thursday issued new warnings that the virus is still spiraling out of control, only in the form of a rolling series of outbreaks in almost half the states, with more troubling signs in many others. (Doherty, 7/23)

The Hill: Trump Likely To Sign Executive Orders On Drug Pricing Friday President Trump is likely to sign executive orders on Friday aimed at lowering drug prices, elevating a key issue for voters in an election year.While the plans could shift at the last minute, some GOP lawmakers have been invited to a presidential event on drug pricing Friday at 3 p.m. at the White House in the South Court Auditorium to make the announcement, according to an invitation obtained by The Hill. (Sullivan, 7/23)

The New York Times: Trump Moves To Roll Back Obama Program Addressing Housing Discrimination The rule, introduced in 2015, requires cities and towns to identify patterns of discrimination, implement corrective plans and report results. The administrations decision to complete a process of rescinding it culminates a yearslong campaign to gut the rule by conservative critics and members of the administration who claimed it overburdened communities with complicated regulations. (Fuchs, 7/23)

Los Angeles Times: Trump Repeals Housing Rule, Amplifying Appeals To Racial Bias With President Trump facing sagging support in the suburbs, his administration on Thursday targeted an Obama-era affordable housing regulation, the latest in a series of appeals to white voters fears of crime and declining property values. The U.S. Department of Housing and Urban Development announced that it would scrap a regulation known as Affirmatively Furthering Fair Housing, which was implemented by President Obama in an attempt to promote more integrated communities. Under the rule, cities receiving some federal housing aid had to develop plans to address patterns of segregation or risk losing money. (Megerian, Dillon and Stokols, 7/23)

Politico: Trump Administration Renews Public Health Emergency After Urging From States The Trump administration has renewed the public health emergency for the coronavirus, ensuring that critical resources to fight the pandemic can continue while much of the country battles rising caseloads. The news will come as relief to health care groups who worried that President Donald Trump would let the emergency declaration lapse when it was set to expire July 25, despite previous assurances from top administration officials it would be renewed. (Roubein, 7/23)

Politico: Trump Warns Of 'Greater Mortality' If Schools Don't Reopen President Donald Trump is still demanding schools reopen, even after nixing his Republican National Convention keynote events in Florida next month. The president argued Thursday that "a permanent shutdown was never the strategy, which would ultimately lead to greater mortality and irreversible harm." The prosperity of the U.S. economy hinges on children returning to school in person this fall, he contended, noting that the Council of Economic Advisers has estimated more than 5 million parents won't be able to go back to work if their kids don't return to campus. (Quilantan and Miranda Ollstein, 7/23)

AP: In Shift, Trump Says Some Schools May Need To Delay Opening Softening his earlier stance, President Donald Trump on Thursday acknowledged that some schools may need to delay their reopening this fall as the coronavirus continues to surge. It marks a shift from Trumps previous demand for a full reopening of the nations schools. Speaking at a White House news conference, Trump said districts in some virus hot spots may need to delay reopening for a few weeks. He said the decision will fall to governors. (Binkley, 7/23)

The Hill: Trump Cancels GOP Convention Plans In Jacksonville President Trump said Thursday that he would cancel the GOP convention events in Jacksonville, Fla., in August, saying it wasnt the right time due to the coronavirus. I told my team it's time to cancel the Jacksonville component of the GOP convention, Trump told reporters at a news conference at the White House. Ill still do a convention speech in a different form, but we wont do a big crowded conventionper se. Its just not the right time for that." (Chalfant, 7/23)

The New York Times: Trump Abruptly Cancels Republican Convention In Jacksonville: Its Not The Right Time The surprise announcement threw one of the tent-pole moments of Mr. Trumps re-election effort into limbo, with the president describing in vague terms how the Republicans would hold his renomination in North Carolina and do other things with tele-rallies and online. It was an ill-defined sketch of an August week that Mr. Trump once envisioned drawing huge crowds and energizing his struggling bid for a second term. (Haberman, Mazzei and Karni, 7/23)

Politico: How Trump Went From A Massive Convention Bash To No Party At All On Wednesday evening, President Donald Trump convened his top political advisers, including campaign manager Bill Stepien and Republican National Committee Chairwoman Ronna McDaniel, for a conference call to consider a move that would have been unthinkable just a few weeks ago: Cancel his partys upcoming convention in Jacksonville, Fla. By Thursday afternoon, with coronavirus raging in the state, the president who all year envisioned a boisterous send-off to the final months of his reelection campaign, had made up his mind: It was a no-go. (Isenstadt, Dixon and Fineout, 7/23)

The Hill: Trump Administration Recommends Against Universities Requiring COVID-19 Tests Before Students Return The Trump administration said Thursday it is not recommending universities require students be tested for COVID-19 before they head back to campus this fall. In general, testing people before going back to the university is not a strategy that we recommend, nor does the CDC recommend, because you're only negative for that one moment, Adm. Brett Giroir, assistant secretary at the Department of Health and Human Services who is in charge of COVID-19 testing strategy, told reporters. (Hellmann, 7/23)

The Hill: Fauci: With Vaccine, 'We Could Start Talking About Real Normality Again' In 2021 The completion of a coronavirus vaccine could allow the U.S. to return to real normality in 2021, Anthony Fauci, the nations top infectious diseases expert, said Thursday. "The timetable of getting into 2021, well into the year, then I can think with a successful vaccine if we could vaccinate the overwhelming majority of the population we could start talking about real normality again," Fauci said Thursday on CNN contributor David Axelrods podcast The Axe Files. "But it is going to be a gradual process." (Budryk, 7/23)

The Hill: Fauci Says That He And His Family Have Experienced 'Serious Threats' During Pandemic Anthony Fauci, the nations top infectious diseases expert, said Thursday that he has received serious threats to himself and his family since he became one of the public faces of the federal response to the coronavirus pandemic. The doctor said that the anger has appeared on a different level than when he began his work during the HIV/AIDS crisis. (Budryk, 7/23)

The Hill: Birx Warns Of Disturbing Rise Of Coronavirus Cases In 12 Cities White House coronavirus task force coordinator Deborah Birx saidin a private meeting with local and state health officials that the task force is tracking increases in the virus in 12 U.S. cities. "There are cities that are lagging behind and we have new increases in Miami, New Orleans, Las Vegas, San Jose, St. Louis, Indianapolis, Minneapolis, Cleveland, Nashville, Pittsburgh, Columbus and Baltimore, so we're tracking this very closely, Birx said in the audio, first obtainedby the nonprofit Center for Public Integrity. We're working with the state officials to make sure we're responding together, but when you first see that increased test positivity, that is when to start the mitigation efforts." (Budryk, 7/23)

The Hill: Obama: US Not Dealing With Coronavirus As 'Smartly' As Other Countries Former President Obama saidin remarks released Thursdaythat the U.S. is not dealing with the coronavirus pandemic as smartly as other countries with similar resources. The former president made the remarks during a conversation with presumptive Democratic presidential nominee Joe Biden, saying he was confident that if his former vice president is elected in November he will respond to the crisis effectively. (Klar, 7/23)

NBC News: Despite Judge's Order, Migrant Children Remain Detained Amid COVID Outbreak Nearly a month after a federal judge ruled the Trump administration must release migrant children "with all deliberate speed" from Immigration and Customs Enforcement detention centers because of COVID-19, 346 parents and children are detained in facilities with outbreaks and court filings show releases remain rare. When U.S. District Judge Dolly Gee ordered the release of children detained with their parents in late June, she was explicit in her reasoning. The ICE facilities, she said, were "on fire and there is no more time for half measures." (Soboroff, 7/23)

Politico: Marine Assigned To Trump's Helicopter Squadron Tests Positive For Covid-19 A Marine assigned to the military helicopter squadron responsible for transporting the president has tested positive for Covid-19, a Marine Corps spokesperson told POLITICO. The Marine, assigned to Marine Helicopter Squadron 1, was tested on Tuesday and received the positive result on Thursday, said spokesperson Capt. Joseph Butterfield, adding that the squadron administers 80 to 100 tests per week. (Seligman, Lippman and Caputo, 7/23)

The New York Times: Republican Stimulus Talks Stall Over Differences On Unemployment Republicans stumbled on Thursday in their efforts to find agreement on a broad new proposal to lift the struggling economy, with Senate leaders and the Trump administration at odds over multiple provisions, including how to extend unemployment benefits and White House requests for spending unrelated to the pandemic. Even after President Trump folded on one of his key demands, for a payroll tax cut, negotiations bogged down over details of the package, including how to reduce the amount of money that Americans are currently receiving as unemployment benefits. (Cochrane, Tankersley and Rappeport, 7/23)

The Hill: Senate GOP Punts Coronavirus Package To Next Week GOP senators expected to introduce the package of bills on Thursday after days of closed-door haggling among themselves and the White House and publicly struggling to get on the same page. But Senate Majority Leader Mitch McConnell (R-Ky.) said key senators will instead unveil it Monday, pointing at the White House as the reason behind the delay. (Carney, 7/23)

Politico: As Unemployment Grows, White House And Senate GOP Stumble On Virus Talks Senate Republicans were forced to delay the rollout of a $1 trillion coronavirus relief package after differences between the White House and GOP leadership derailed the timing for unveiling the measure an embarrassing setback that could have serious consequences for millions of unemployed Americans. The main area of dispute was over extension of federal unemployment assistance for workers that have lost their jobs as the United States economy shut down during in response to the coronavirus pandemic. These $600-per-week payments begin to expire this week. Just on Thursday, the federal government announced that 1.4 million new unemployment claims had been filed in the past week. (Bresnahan and Levine, 7/23)

AP: Jobless Claims Rise As Cutoff Of Extra $600 Benefit Nears The nation got another dose of bad economic news Thursday as the number of laid-off workers seeking jobless benefits rose for the first time since late March, intensifying concerns the resurgent coronavirus is stalling or even reversing the economic recovery. And an extra $600 in weekly unemployment benefits, provided by the federal government on top of whatever assistance states provide, is set to expire July 31, though this is the last week recipients will get the extra funds. It is the last major source of economic help from the $2 trillion relief package that Congress approved in March. A small business lending program and one-time $1,200 payment have largely run their course. (Rugaber, 7/24)

The New York Times: Heres How Congress Might Replace The Extra $600 Weekly Jobless Benefit An additional $600 per week that has provided a vital financial cushion for unemployed Americans is set to expire next week. On Thursday, top Republicans said they had reached agreement on a proposal to replace a benefit that has helped millions of laid-off workers and been a boon to consumer spending amid a deep recession. Their plan would continue to offer larger-than-normal payments to workers filing for unemployment benefits. But it would significantly reduce the amount of money flowing each week to those without a job, at a time when 30 million people remain unemployed and the recovery from a pandemic recession is stuck in the mud. (Tankersley and Casselman, 7/23)

The Hill: Democrats Hit Interior Secretary For Reportedly Refusing To Wear Mask In Meeting With Tribes Three Democratic senators are criticizingInterior Secretary David Bernhardtover reports that he refused to wear a mask in a meeting with tribes in Oregon earlier this month. On your July 9 visit with the Klamath Tribes of Oregon, the tribe expressed concerns that you and a member of the U.S. House of Representatives from the State of California refused to wear a mask wrote Democratic Sens. Elizabeth Warren (Mass.), Ron Wyden (Ore.) and Jeff Merkley (Ore.). (Frazin, 7/23)

The Wall Street Journal: China Says It Will Have Covid-19 Vaccine Ready This Year One of the first Chinese projects to start testing its Covid-19 vaccine candidates overseas said it would have a vaccine ready for the public before the end of the year. Liu Jingzhen, chairman of state-owned China National Pharmaceutical Group, also known as Sinopharm, said on state broadcaster CCTV on Tuesday that clinical trials that began in Abu Dhabi last week should be completed in roughly three months, paving the way for a vaccine to go to the market this year. (Deng, 7/23)

The New York Times: Who Gets The Covid-19 Vaccine First? Heres One Idea When a coronavirus vaccine becomes available, who should get it first? A preliminary plan devised by the Centers for Disease Control and Prevention this spring gives priority to health care workers, then to people with underlying medical conditions and older people. The C.D.C. has not yet decided whether the next in line should be Blacks and Latinos, groups disproportionately affected by the coronavirus .But lets suppose that health care workers and people with underlying medical conditions use up the first doses of the available vaccine. Should some be held in reserve for Black and Latino people? What about bus drivers and train conductors? Perhaps teachers or schoolchildren should get it so they can return to classrooms with peace of mind. (Kolata, 7/23)

Stat: Ruling Threatens To Upend Patents On Modernas Covid-19 Vaccine Moderna, racing to develop a vaccine for Covid-19, lost a key patent decision Thursday, one that could delay the companys progress or force it to hand over a cut of profits. The U.S. Patent and Trademark Office denied Modernas claim that a patent held by a rival company was invalid. The patent, which covers technology used to deliver messenger RNA treatments, is held by the Canadian firm Arbutus. (Garde, 7/23)

Stat: Covid-19 Streamlined FDA Rules, And Pharma's Pushing To Keep It That Way The pharmaceutical industry made it clear to the Food and Drug Administration that it wants the regulatory flexibilities the agency has embraced during the Covid-19 pandemic to be made permanent and its ready to push to make sure it happens.There is a pressing need for FDA and industry to identify actions taken during the Covid-19 pandemic and evaluate their effectiveness and applicability to innovative drug development beyond the public health emergency, said Lucy Vereshchagina, vice president of science and regulatory affairs at PhRMA. (Florko, 7/23)

The New York Times: Coronavirus Testing Labs Again Lack Key Supplies Labs across the country are facing backlogs in coronavirus testing thanks in part to a shortage of tiny pieces of tapered plastic. Researchers need these little disposables, called pipette tips, to quickly and precisely move liquid between vials as they process the tests. As the number of known coronavirus cases in the United States passes 4 million, these new shortages of pipette tips and other lab supplies are once again stymieing efforts to track and curb the spread of disease. (Wu, 7/23)

The New York Times: Testing Bottlenecks Threaten N.Y.C.s Ability To Contain Virus Nearly four months after the pandemics peak, New York City is facing such serious delays in returning coronavirus test results that public health experts are warning that the problems could hinder efforts to reopen the local economy and schools. Despite repeated pledges from Gov. Andrew M. Cuomo and Mayor Bill de Blasio that testing would be both widely accessible and effective, thousands of New Yorkers have had to wait a week or more for results, and at some clinics the median wait time is nine days. One prominent local official has even proposed the drastic step of limiting testing. (Goldstein and McKinley, 7/23)

The Wall Street Journal: Baseballs Opening Day Rocked By Covid-19 Tests For Nationals Star Juan Soto After months of detailed drafting, Major League Baseballs return-to-play plan couldnt make it to the seasons first pitch before facing a problem that demonstrates the enormous challenge of playing amid the coronavirus pandemic. About five hours before the Washington Nationals were set to play the first game of the shortened 2020 campaign against the New York Yankees, the team announced that star outfielder Juan Soto had tested positive for Covid-19. Upon finding out Thursday, the 21-year-old Soto took multiple rapid-response coronavirus tests that came back negative, a person familiar with the matter said. Nonetheless, Soto must sit out until he produces two lab-confirmed negative tests, spaced 24 hours apart. The entire episode provided insight into the fragility of baseballs carefully crafted protocolsand how difficult it will be to avoid an outbreak of infection over the next three months. (Diamond and Radnofsky, 7/23)

CIDRAP: Chronic Conditions Put Nearly Half Of US Adults At Risk For Severe COVID-19 About 47% of US adults have an underlying condition strongly tied to severe COVID-19 illness, researchers at the Centers for Disease Control and Prevention (CDC) have found. The model-based study, published today in the CDC's Morbidity and Mortality Weekly Report, used self-reported data from the 2018 Behavioral Risk Factor Surveillance System and the US Census. (Van Beusekom, 7/23)

CIDRAP: Live COVID-19 Virus Isolated From Human Nose-Throat, Saliva Specimens A small study published yesterday in Clinical Microbiology and Infection found live SARS-CoV-2, the virus that causes COVID-19, in one nose-throat swab and two saliva specimens of five infected hospital patients in Korea 11 to 15 days after symptom onset. Researchers collected nose-throat swabs, saliva, urine, and stool samples from the patients hospitalized from Feb 25 to Mar 5 on days 8, 11, 13, 15, and 30 after study enrollment. They performed quantitative reverse transcription-polymerase chain reaction (qRT-PCR) to detect SARS-CoV-2 RNA and cell culture to detect viable virus. No live virusonly viral RNAwas isolated on cell culture from five urine, two saliva, four nose-throat, and three fecal specimens. (7/23)

Stat: Scientists Are Developing Synthetic Biosensors To Monitor Lung Disease Imagine inhaling a sensor that could monitor lung disease patients response to therapy, emitting a signal when they breathe out. Like a breathalyzer that recognizes alcohol, such a device could sniff out compounds released only by specific illnesses to gauge how well treatment is working. Biomedical engineers at the Massachusetts Institute of Technology have developed a synthetic biosensor using specialized nanoparticles to detect and then report the presence of molecules indicating bacterial pneumonia or the genetic disease alpha-1 antitrypsin deficiency. (Cooney, 7/24)

AP: FDA Tells Doctors To Discuss Overdose Antidote With Patients Prescribing instructions for all opioids, such as Percocet and OxyContin, will recommend doctors discuss how to get the overdose-reversal drug, which can be obtained from pharmacists without a prescription. For patients with a higher risk of overdose, such as those with a history of opioid addiction, doctors should consider prescribing naloxone alongside the opioid. The same recommendations will appear on drugs used to control opioid addiction, such as methadone. (Perrone, 7/23)

Stat: FDA Says Opioid Labels Must Include Information About Naloxone The Food and Drug Administration announced Thursday that it would require drug manufacturers to include information about naloxone, the overdose-reversal medication, on the labels of opioid painkillers. The move comes just weeks after the federal government released new data showing that U.S. drug overdose deaths reached an all-time high in 2019, surpassing the previous peak recorded two years earlier. (Facher, 7/23)

The New York Times: How Play Energizes Your Kids Brain To the untrained eye, play can seem aimless, repetitive, wild or foolish. But play can offer a window into the developing mind. Piaget viewed certain kinds of play as milestones, signs that a child had reached a new stage of development. Studies conducted over the past few decades suggest play serves a more crucial role. Play can help kids learn, plan and even persevere in the face of adversity. (Willyard, 7/21)

The New York Times: Should 5-Year-Olds Start School This Year? Alka Tripathy-Langs 5-year-old son is supposed to start kindergarten this fall, but her district in suburban Phoenix has already delayed its start and announced that classes, when they do start, will be online for at least the first couple of weeks. What those lessons will look like is unclear, as are details about how much parental involvement will be required, and how or when the school is going to implement the dual immersion Mandarin program her son is supposed to begin. Tripathy-Langs current plan is to start him in an online-only option, but if its not working, shell pull him out to be home with her 3-year-old, who she and her husband have already decided not to send to preschool this year. (Sohn, 7/23)

The Washington Post: Librarians Alarmed About Coronavirus Safety At D.C.s Reopened Public Libraries When the Districts public libraries began gradually reopening in late May, many residents rushed to check out books for the first time in six weeks. By mid-July, the library was opening its doors for six hours a day, five days a week, for patrons who could come inside to borrow items and spend time using public computers at 14 locations. But librarians say the reopening has been poorly handled, exposing both staff members and the public to potential coronavirus risks. They also say library managers have kept staff in the dark about colleagues who come down with the virus and have struggled with cleaning protocols and mask requirements. (Zauzmer, 7/23)

The Wall Street Journal: Face Masks And A Mohel: Parents Figure Out How To Host A Bris During Coronavirus When Ben Sass and Aliza Jaffe Sass learned in January that they had a baby boy on the way, preparations for a bris started immediately. Along with the rest of the logistical advance work of pregnancy, they now had to decide which family members would have the honors of escorting their new son into the ceremony, who would hold the child during the circumcision procedure, and what they would serve their guests at the reception afterward. They didnt plan for how they would facilitate a surgery on an infant in their Philadelphia apartment during a global pandemic. (Rubin, 7/23)

CIDRAP: Nearly 60% Of US Parents Say They Won't Vaccinate Their Kids Against HPV Nearly 60% of the parents of about 4.3 million US children don't intend to have them vaccinated against the highly infectious and sexually transmitted human papillomavirus (HPV), according to survey results published earlier this week in The Lancet Public Health. Researchers at the University of Texas at Houston analyzed the data of parents of 82,297 children 13 to 17 years old from the 2017-18 National Immunization Study. They found even higher vaccine hesitancy rates (higher than 65%) in Idaho, Kansas, Michigan, Montana, Nebraska, North Dakota, Oklahoma, and Utah. (7/23)

Stat: New Research Finds A Wide Gulf In Engagement With Mental Health Apps A first-of-its-kind analysis, conducted in collaboration with researchers at Microsoft, paints a detailed picture of how people do or dont engage with virtual mental health tools, a step toward expanding the use of digital therapeutics. Lackluster engagement has long been a thorn in the health tech industrys side: As mental health tools proliferate, their uptake and long-term use remain relatively low. That problem has taken on new urgency as the pandemic shunts patients from in-person to online treatment. (Isselbacher, 7/24)

AP: Lawyer Defends Actions Of Vets Home Boss Amid Outbreak A Massachusetts home where nearly 80 aging veterans sicked with the coronavirus have died was denied emergency aid as leadership and staff frantically worked to protect the residents, an attorney for the ousted superintendent said Thursday. The attorney said state officials initially refused in March to send National Guard aid even as the home was dealing with dire staffing shortages. The lawyer for former Holyoke Soldiers Home Superintendent Bennett Walsh called him a good and honorable man who would never do anything intentional to harm the vets. (Durkin Richer, 7/23)

AP: Restraining Order Barring Nursing Home Closing Extended A southern Illinois judge on Thursday extended a temporary restraining order barring a nursing home from executing its closure plan until it has fulfilled all its obligations to residents. When Aperion Care Cairo announced its intention to close last week, families complained to Alexander County officials they felt rushed to select alternative placement for loved ones. (7/23)

The Washington Post: Meatpacking Workers File Lawsuit Against OSHA, Accusing Agency Of Failing To Keep Them Safe The Occupational Safety and Health Administration is failing to do its job properly, according to a lawsuit filed Thursday by three meatpacking workers, who say the agencys inaction has left them in danger. The lawsuit accuses OSHA of leaving the workers in imminent danger due to what they say are hazardous working conditions at the factory where they work, run by Maid-Rite Specialty Foods in Pennsylvania, in the midst of the coronavirus pandemic. (Rosenberg, 7/23)

Los Angeles Times: How To Say No To Parties During The COVID-19 Pandemic Of course you are allowed to say no. You are allowed to say that at all times, to all invitations, under all circumstances. But especially right now, in the middle of a pandemic. So its less about whether you can say it and more about how, experts say. Tone matters. Put a smile on your face when you make the call and keep it simple: Thank you for the invitation, Im so sorry but I cant make it. (Roy, 7/23)

Reuters: Georgia's Governor And Atlanta's Mayor Ordered To Mediate Coronavirus Mask Fight A Georgia judge on Thursday ordered the governor and Atlantas mayor to enter mediation over the governors lawsuit aimed at stopping the city from enforcing its requirement that people wear masks in public during the coronavirus pandemic. Fulton Superior Court Judge Jane Barwick ordered Governor Brian Kemp and Mayor Keisha Lance Bottoms to attend mediation with another judge and try to resolve the dispute before an emergency hearing scheduled in the case for Tuesday. (McKay, 7/23)

AP: Anchorage Mayor To Impose New Restrictions Amid Virus Cases The mayor of Anchorage is limiting gathering sizes and the number of people allowed in bars, restaurants and entertainment venues in response to rising coronavirus cases. The order, by Mayor Ethan Berkowitz, takes effect Friday and says that due to a resurgence in cases there is a need for increased restrictions on public interactions to preserve health and save lives in our community. (Bohrer, 7/23)

AP: North Dakota Governor Blasts Party's Anti-LGBTQ Resolution North Dakotas Republican governor on Thursday blasted an anti-LGBTQ resolution that was passed by hundreds of his partys delegates, calling it insulting and divisive. The resolution one of dozens of party policy statements in a passed by this spring by mail-in ballot states that many LGBT practices are unhealthy and dangerous, sometimes endangering or shortening life and sometimes infecting society at large. Gov. Doug Burgum issued a statement Thursday denouncing the resolution. (MacPherson, 7/23)

The Hill: Two Florida Mayors Urge Residents To Wear Masks At Home Two Florida mayorswho governMiami and Miami-Dade County encouraged their residents on Thursday to wear masks inside to lower the transmission rate of COVID-19 between family members. Miami Mayor Francis Suarez (R) explained that while the city's number of daily new cases is down, the virus is still being spread easily through households, as multigenerational households are commonplace in Miami. (Johnson, 7/23)

Stat: San Francisco Official Pushes City To Condemn Hospitals Zuckerberg Name A San Francisco city official is introducing a resolution to condemn the citys public hospital for naming itself after Mark Zuckerberg the latest escalation of a five-year quest, led mostly by nurses and other health care workers, to disassociate the institution from the controversial Facebook founder. The resolution, introduced late Thursday by San Francisco supervisor Gordan Mar, wouldnt strip the hospital of the Zuckerberg name, bestowed on the hospital after he and his wife, pediatrician Priscilla Chan, donated $75 million to the institution in 2015. (Ortolano, 7/24)

AP: 6 Downstate Illinois Counties Sue Over COVID-19 Restrictions Residents in six central and southern Illinois counties, including the state capitals home, filed lawsuits Thursday against Gov. J.B. Pritzkers restrictions on social interaction prompted by the coronavirus pandemic. The actions taken in Bond, Clay, Clinton, Edgar, Richland and Sangamon counties seek court orders declaring there is no public health emergency as defined by Pritzkers Public Health Department. Springfield, the state capital, is in Sangamon County. (7/24)

AP: Inslee Shuts Indoor Service At Bars, Restricts Indoor Dining Washington Gov. Jay Inslee said Thursday he is tightening restrictions throughout the state in restaurants and bars, for weddings and funerals, and at gyms in a further effort to stem a surge in COVID-19 cases. I care about businesses opening and people getting back to work, but public health and economic activity go hand in hand, Inslee said. If we let this virus get even more out of control, it will have devastating effects on our health and on our economy. (Baumann, 7/24)

Link:
First Edition: July 24, 2020 - Kaiser Health News

Cell Therapy Market Analysis Of Global Trends, Demand And Competition 2020-2028 – Owned

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Cell Therapy market.

Trusted Business Insights presents an updated and Latest Study on Cell Therapy Market 2019-2026. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Cell Therapy market during the forecast period (2019-2029). It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Cell Therapy Market Size, Share, Market Research and Industry Forecast Report, 2020-2027 (Includes Business Impact of COVID-19)

Industry Insights, Market Size, CAGR, High-Level Analysis: Cell Therapy Market

The global cell therapy market size was valued at USD 5.8 billion in 2019 and is projected to witness a CAGR of 5.4% during the forecast period. The development of precision medicine and advancements in Advanced Therapies Medicinal Products (ATMPS) in context to their efficiency and manufacturing are expected to be the major drivers for the market. In addition, automation in adult stem cell and cord blood processing and storage are the key technological advancements that have supported the growth of the market for cell therapy. The investment in technological advancements for decentralizing manufacturing of this therapy is anticipated to significantly benefit the market. Miltenyi Biotec is one of the companies that has contributed to the decentralization in manufacturing through its CliniMACS Prodigy device. The device is an all-in-one automated manufacturing system that exhibits the capability of manufacturing various cell types.

An increase in financing and investments in the space to support the launch of new companies is expected to boost the organic revenue growth in the market for cell therapy. For instance, in July 2019, Bayer invested USD 215 million for the launch of Century Therapeutics, a U.S.-based biotechnology startup that aimed at developing therapies for solid tumors and blood cancer. Funding was further increased to USD 250 billion by a USD 35 million contribution from Versant Ventures and Fujifilm Cellular Dynamics. The biomanufacturing companies are working in collaboration with customers and other stakeholders to enhance the clinical development and commercial manufacturing of these therapies. Biomanufacturers and OEMs such as GE healthcare are providing end-to-end flexible technology solutions to accelerate the rapid launch of therapies in the market for cell therapy. The expanding stem cells arena has also triggered the entry of new players in the market for cell therapy. Celularity, Century Therapeutics, Rubius Therapeutics, ViaCyte, Fate Therapeutics, ReNeuron, Magenta Therapeutics, Frequency Therapeutics, Promethera Biosciences, and Cellular Dynamics are some startups that have begun their business in this arena lately. Use-type Insights The clinical-use segment is expected to grow lucratively during the forecast period owing to the expanding pipeline for therapies. The number of cancer cellular therapies in the pipeline rose from 753 in 2018 to 1,011 in 2019, as per Cancer Research Institute (CRI). The major application of stem cell treatment is hematopoietic stem cell transplantation for the treatment of the immune system and blood disorders for cancer patients. In Europe, blood stem cells are used for the treatment of more than 26,000 patients each year. These factors have driven the revenue for malignancies and autoimmune disorders segment. Currently, most of the stem cells used are derived from bone marrow, blood, and umbilical cord resulting in the larger revenue share in this segment. On the other hand, cell lines, such as Induced Pluripotent Stem Cells (iPSC) and human Embryonic Stem Cells (hESC) are recognized to possess high growth potential. As a result, a several research entities and companies are making significant investments in R&D pertaining to iPSC- and hESC-derived products. Therapy Type Insights of Cell Therapy Market

An inclination of physicians towards therapeutic use of autologous and allogeneic cord blood coupled with rising awareness about the use of cord cells and tissues across various therapeutic areas is driving revenue generation. Currently, the allogeneic therapies segment accounted for the largest share in 2019 in the cell therapy market. The presence of a substantial number of approved products for clinical use has led to the large revenue share of this segment.

Furthermore, the practice of autologous tissue transplantation is restricted by the limited availability of healthy tissue in the patient. Moreover, this type of tissue transplantation is not recommended for young patients wherein tissues are in the growth and development phase. Allogeneic tissue transplantation has effectively addressed the above-mentioned challenges associated with the use of autologous transplantation. However, autologous therapies are growing at the fastest growth rate owing to various advantages over allogeneic therapies, which are expected to boost adoption in this segment. Various advantages include easy availability, no need for HLA-matched donor identification, lower risk of life-threatening complications, a rare occurrence of graft failure, and low mortality rate.

Regional Insights of Cell Therapy Market

The presence of leading universities such as the Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, and Yale Stem Cell Center that support research activities in U.S. is one of the key factor driving the market for cell therapy in North America. Moreover, strong regulatory and financing support from the federal bodies for expansion of this arena in U.S. as well as Canada is driving the market. In Asia Pacific, the market is anticipated to emerge as a lucrative source of revenue owing to the availability of therapies at lower prices coupled with growing awareness among the healthcare entities and patients pertaining the potential of these therapies in chronic disease management. Japan is leading the Asian market for cell therapy, which can be attributed to its fast growth as a hub for research on regenerative medicine. Moreover, the Japan government has recognized regenerative medicine and cell therapy as a key contributor to the countrys economic growth. This has positively influenced the attention of global players towards the Asian market, thereby driving marketing operations in the region.

Market Share Insights of Cell Therapy Market

Some key companies operating in this market for cell therapy are Fibrocell Science, Inc.; JCR Pharmaceuticals Co. Ltd.; Kolon TissueGene, Inc.; PHARMICELL Co., Ltd.; Osiris Therapeutics, Inc.; MEDIPOST; Cells for Cells; NuVasive, Inc.; Stemedica Cell Technologies, Inc.; Vericel Corporation; and ANTEROGEN.CO.,LTD. These companies are collaborating with the blood centers and plasma collection centers in order to obtain cells for use in therapeutics development. Several companies have marked their presence in the market by acquiring small and emerging therapy developers. For instance, in August 2019, Bayer acquired BlueRock Therapeutics to establish its position in the market for cell therapy. BlueRock Therapeutics is a U.S. company that relies on a proprietary induced pluripotent stem cell (iPSC) platform for cell therapy development. Several companies are making an entry in the space through the Contract Development and Manufacturing Organization (CDMO) business model. For example, in April 2019, Hitachi Chemical Co. Ltd. acquired apceth Biopharma GmbH to expand its global footprint in the CDMO market for cell and gene therapy manufacturing.

Segmentations, Sub Segmentations, CAGR, & High-Level Analysis overview of Cell Therapy Market Research Report This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2019 to 2030. For the purpose of this study, this market research report has segmented the global cell therapy market on the basis of use-type, therapy-type, and region:

Use-Type Outlook (Revenue, USD Million, 2019 2030)

Clinical-use

By Therapeutic Area

Malignancies

Musculoskeletal Disorders

Autoimmune Disorders

Dermatology

Others

By Cell Type

Stem Cell Therapies

BM, Blood, & Umbilical Cord-derived Stem Cells

Adipose derived cells

Others

Non-stem Cell Therapies

Research-use

Therapy Type Outlook (Revenue, USD Million, 2019 2030)

Allogeneic Therapies

Autologous Therapies

Quick Read Table of Contents of this Report @ Cell Therapy Market Size, Share, Market Research and Industry Forecast Report, 2020-2027 (Includes Business Impact of COVID-19)

Trusted Business Insights Shelly Arnold Media & Marketing Executive Email Me For Any Clarifications Connect on LinkedIn Click to follow Trusted Business Insights LinkedIn for Market Data and Updates. US: +1 646 568 9797 UK: +44 330 808 0580

More here:
Cell Therapy Market Analysis Of Global Trends, Demand And Competition 2020-2028 - Owned

Scientists discovered the real reason behind goosebumps – Tech Explorist

Human bodies do a lot of weird stuff. But goosebumps may be one of our strangest bodily functions.

Goosebumps are humanitys near-universal reaction to the cold. But for some reason, those unmistakable, tiny bumps on the skin also appear when were scared or when were moved by something awe-inspiring.

A new has discovered the reason behind goosebumps. Scientists from Harvard University suggested that the cells that cause goosebumps are also important for regulating the stem cells that regenerate hair.

Underneath the skin, the muscle that contracts to make goosebumps is essential to connect the sympathetic nerves connection with hair follicle stem cells. The sympathetic nerve responds to cold by contracting the muscle and causing goosebumps in the short term, and by driving hair follicle stem cell activation and new hair development over the long term.

The study was conducted on mice, offers a better comprehension of how different cell types interact to link stem cell activity with changes in the outside environment.

Ya-Chieh Hsu, the Alvin and Esta Star Associate Professor of Stem Cell and Regenerative Biology said,We have always been interested in understanding how stem cell behaviors are regulated by external stimuli. The skin is a fascinating system: it has multiple stem cells surrounded by diverse cell types and is located at the interface between our body and the outside world. Therefore, its stem cells could potentially respond to a diverse array of stimuli from the niche, the whole body, or even the outside environment.

In this study, we identify an interesting dual-component niche that not only regulates the stem cells under steady-state but also modulates stem cell behaviors according to temperature changes outside.

In the skin, three types of tissues (epithelium, mesenchyme, and nerve) are organized in a special arrangement. The sympathetic nerve, part of our nervous system that controls body homeostasis and our responses to external stimuli, connects with a tiny smooth muscle in the mesenchyme. This smooth muscle in turn connects to hair follicle stem cells, a type of epithelial stem cell critical for regenerating the hair follicle as well as repairing wounds.

The connection between the thoughtful nerve and the muscle has been notable since they are the cellular basis behind goosebumps: the cold triggers sympathetic neurons to send a nerve signal, and the muscle reacts by contracting and making the hair stand on end.

However, when examining the skin under extremely high resolution using electron microscopy, scientists demonstrated that the sympathetic nerve not only associated with the muscle but also formed a direct connection to the hair follicle stem cells. In fact, the nerve fibers wrapped around the hair follicle stem cells like a ribbon.

Hsu said,We could really see at an ultrastructure level how the nerve and the stem cell interact. Neurons tend to regulate excitable cells, like other neurons or muscles with synapses. But we were surprised to find that they form similar synapse-like structures with an epithelial stem cell, which is not a very typical target for neurons.

Next, the analysts affirmed that the nerve in fact targeted the stem cells. The sympathetic nervous system is normally initiated at a consistently low level to keep up body homeostasis, and the scientists found that this low level of nerve activity kept up the stem cells in a poised state ready for regeneration. Under prolonged cold, the nerve was enacted at a lot higher level and more neurotransmitters were released, making the stem cells actuate rapidly, recover the hair follicle, and grow new hair.

Scientists also investigated what maintained the nerve connections to the hair follicle stem cells. Removing the sympathetic nerve retracted and the nerve connection to the hair follicle stem cells was lost. It shows that the muscle was necessary for structural support to bridge the sympathetic nerve to the hair follicle.

Yulia Shwartz, a postdoctoral fellow in the Hsu lab said,We discovered that the signal comes from the developing hair follicle itself. It secretes a protein that regulates the formation of the smooth muscle, which then attracts the sympathetic nerve. Then in the adult, the interaction turns around, with the nerve and muscle together regulating the hair follicle stem cells to regenerate the new hair follicle. Its closing the whole circle the developing hair follicle is establishing its own niche.

Through this study, scientists also discovered a two-component system that regulates hair follicle stem cells. The nerve is the signaling component that activates the stem cells through neurotransmitters, while the muscle is the structural component that allows the nerve fibers to directly connect with hair follicle stem cells.

Shwartz said,You can regulate hair follicle stem cells in so many different ways, and they are wonderful models to study tissue regeneration. This particular reaction is helpful for coupling tissue regeneration with changes in the outside world, such as temperature. Its a two-layer response: goosebumps are a quick way to provide some sort of relief in the short term. But when the cold lasts, this becomes a nice mechanism for the stem cells to know its maybe time to regenerate new hair coat.

Scientists are further planning to investigate the way the external environment might influence the stem cells in the skin, both under homeostasis and in repair situations such as wound healing.

Hsu said,We live in a constantly changing environment. Since the skin is always in contact with the outside world, it gives us a chance to study what mechanisms stem cells in our body use to integrate tissue production with changing demands, which is essential for organisms to thrive in this dynamic world.

Follow this link:
Scientists discovered the real reason behind goosebumps - Tech Explorist

Stem Cell Banking Industry 2020-Covid-19 Impact on Market Research by Size, Top Leading Countries, Companies, Consumption, Drivers, Trends, Forces…

Data Bridge Market Research announces the release of the reportStem Cell Banking MarketSize, Share & Trends Analysis Report By 2027. This report highlights key market dynamics of Stem Cell Banking industry and covers historic data, present market trends, environment, technological innovation, upcoming technologies and the technical progress in the related industry. This Stem Cell Banking report provides current as well as upcoming technical and financial details of the industry to 2027. Depending on clients demand, huge amount of business, product and market related information has been brought together via this industry report that eventually helps businesses create better strategies. All of these features are strictly applied while building this Stem Cell Banking Market 2020 report for a client. It gives explanation about various definitions and segmentation or classifications of the industry, applications of the industry and value chain structure.

Download Free Sample (350 Pages PDF) Report: To Know the Impact of COVID-19 on this[emailprotected]https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-stem-cell-banking-market

KNOW YOUR OPTIONS IN THE FIGHT AGAINST COVID-19

The COVID-19 Pandemic has created bottlenecks across industry pipelines, sales funnels, and supply chain activities. This has created unprecedented budget pressure on company spending for industry leaders. This has increased requirement for opportunity analysis, price trend knowledge and competitive outcomes. Use the DBMR team to create new sales channels and capture new markets previously unknown. DBMR helps its clients to grow in these uncertain markets.

The Increased Market Growth can be identified by the increasing procedures of hematopoietic stem cell transplantation (hsct), emerging technologies for stem cell processing, storage and preservation. Increasing birth rates, awareness of stem cell therapies and higher treatment done viva stem cell technology. Data Bridge Market Research has recently announced publishing of a report, titled Global Stem Cell Banking Market Industry Trends and Forecast to 2026 As per the report, Global stem cell banking market is set to witness a substantial CAGR of 11.03% in the forecast period of 2019- 2026. The Stem Cell Banking Market report provides the details related to fundamental overview, development status, latest advancements, market dominance and market dynamics. The report also presents the evaluation of the competitive landscape of the market.

Few Of The Major Competitors Currently Working In The Global Stem Cell Banking Market AreNSPERITE N.V, Caladrius, ViaCord, CBR Systems, Inc, SMART CELLS PLUS, LifeCell International, Global Cord Blood Corporation, Cryo-Cell International, Inc., StemCyte India Therapeutics Pvt. Ltd, Cordvida, ViaCord, Cryoviva India, Vita34 AG, CryoHoldco, PromoCell GmbH, Celgene Corporation, BIOTIME, Inc., BrainStorm Cell Therapeutics and others.

Market Definition: Global Stem Cell Banking Market

Stem cells are cells which have self-renewing abilities and segregation into numerous cell lineages. Stem cells are found in all human beings from an early stage to the end stage. The stem cell banking process includes the storage of stem cells from different sources and they are being used for research and clinical purposes. The goal of stem cell banking is that if any persons tissue is badly damaged the stem cell therapy is the cure for that. Skin transplants, brain cell transplantations are some of the treatments which are cured by stem cell technique.

Explore Key Industry Insights In 60 Tables And 220 Figures From The 350 Pages Of Report, Global Stem Cell Banking MarketBy Source (Placental Stem Cells (PSCs), Human Embryo-Derived Stem Cells (hESCs), Bone Marrow-Derived Stem Cells (BMSCs), o Dental Pulp-Derived Stem Cells (DPSCS), Adipose Tissue-Derived Stem Cells (ADSCs) and Other Stem Cell Sources), By Application (Personalized Storage, Clinical, Research), Service Type (Sample Collection and Transportation, Sample Processing, Sample Analysis, Sample Preservation and Storage), Geography (North America, Europe, Asia Pacific, Latin America and The Middle East and Africa) Industry Trends and Forecast to 2026.

The global Stem Cell Banking market report covers scope and product overview to define key terms and offers detailed information about market dynamics to the readers. This is followed by a regional outlook and segmental analysis. The report also consists of the facts and key values of the global Stem Cell Banking market, in terms of sales and volume, revenue and its growth rate.

One of the important factors in the global Stem Cell Banking market report is competitive analysis. The report covers all of the key parameters, such as product innovation, market strategies of the key players, market share, revenue generation, the latest research and development and market experts views.

Inquire More or Share Questions if Any before the Purchase on This Report @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-stem-cell-banking-market

The report focusses on weaknesses and strengths of the global Stem Cell Banking market with a competitive landscape that includes information on some market vendors. Information presented in the report is gathered from primary and secondary research methods. The report also presents recent trends and opportunities of the market helping players strive for the lions share in the market.

Segmentation: Global Stem Cell Banking Market

By Source

By Application

Research

By Service Type

Competitive Analysis: Global Stem Cell Banking Market

The global Stem Cell Banking market is highly fragmented and the major players have used various strategies such as product (software) launches, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of Stem Cell Banking market for global, Europe, North America, Asia Pacific and South America.

Research Methodology: Global Stem Cell Banking Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Primary Respondents

Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.

Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

Reasons to Purchase this Report

Get Direct Order of this Report @https://www.databridgemarketresearch.com/checkout/buy/enterprise/global-stem-cell-banking-market

Research Methodology: Global Stem Cell Banking Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization of the Report

All segmentation provided above in this report is represented at country level.

All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)

Table of Content: Global Stem Cell Banking Market

Continued..

Browse Complete Tables and Figures:https://www.databridgemarketresearch.com/toc/?dbmr=global-stem-cell-banking-market

Follow this link:
Stem Cell Banking Industry 2020-Covid-19 Impact on Market Research by Size, Top Leading Countries, Companies, Consumption, Drivers, Trends, Forces...

Stem Cell Banking Market 2020 Global Trend, Segmentation and Opportunities, Forecast 2026 – 3rd Watch News

Global Stem Cell Banking Marketreport offers an extensive analysis of key drivers, leading market players, key segments, and regions. Besides this, the experts have deeply studied different geographical areas and presented a competitive scenario to assist new entrants, leading market players, and investors determine emerging economies. These insights offered in the report would benefit market players to formulate strategies for the future and gain a strong position in the global market.

Get Sample Copy athttps://www.orianresearch.com/request-sample/1472715

The report first poses the Stem Cell Banking Market basics: definitions, applications, classifications, and market overview; product specifications; manufacturing processes; cost structures, raw materials and more. Further, it assesses the world main region market conditions, including the product price, capacity, production, profit, supply, demand, and market growth rate and forecast etc.

The report offers detailed coverage of Stem Cell Banking industry and main market trends. The market research includes historical and forecast market data, demand, application details, price trends, and company shares of the leading Stem Cell Banking by geography. The report splits the market size, by volume and value, on the basis of application type and geography.

First, this report covers the present status and the future prospects of the global Stem Cell Banking market for 2020-2026. And in this report, we analyze global market from geographies: North America, Europe, China, Japan, Southeast Asia, India, Central & South America

Global Stem Cell Banking Market competition by TOP KEY PLAYERS, with production, price, revenue (value) and each manufacturer including

Inquire More or Share Questions If Any before the Purchase on This Report @https://www.orianresearch.com/enquiry-before-buying/1472715

Global Stem Cell Banking Market Forecast, 2020-2026: The industry research report studies the production, supply, sales, and the current status of the market in a profound manner. Furthermore, the report studies the production shares and market product sales, as well as the capacity, production capacity, sales, and revenue generation. Several other factors such as import/export status, demand, supply, gross margin, and industry chain structure have also been studied in the Global Stem Cell Banking Market report.

Market segment by Type, the product can be split into

Market segment by Application, split into

The competitive landscape of the market has been examined on the basis of market share analysis of key players. Detailed market data about these factors is estimated to help vendors take strategic decisions that can strengthen their positions in the market and lead to more effective and larger stake in the global Stem Cell Banking market. Pricing and cost teardown analysis for products and service offerings of key players has also been undertaken for the study.

Order a Copy of Global Stem Cell Banking Market Report 2020 @https://www.orianresearch.com/checkout/1472715

In short, we are of the conclusion that the global market report provides thorough data for the key players, to clearly understand market deeply. Outstanding players influencing the market through production cost, revenue, share, market size, growth rate, by regional revenue, are enclosed in this report along with the market growth strategies. The report primarily helps to realize and learn the most prohibiting and poignant driving forces of market with anticipating the impacts on the global market.

Table of Content

1 Report Overview

1.1 Study Scope

1.2 Key Market Segments

1.3 Players Covered: Ranking by Stem Cell Banking Revenue

1.4 Market Analysis by Type

1.4.1 Global Stem Cell Banking Market Size Growth Rate by Type: 2020 VS 2026

1.4.2 Ball Gown

1.4.3 Trumpet Dresses

1.4.4 A-line dresses

1.4.5 Mermaid-style Dresses

1.4.6 Sheath Same-day Deliveries

1.4.7 Tea-length Same-day Deliveries

1.4.8 Other

1.5 Market by Application

1.5.1 Global Stem Cell Banking Market Share by Application: 2020 VS 2026

1.5.2 Stem Cell Banking Renting service

1.5.3 Wedding Consultant

1.5.4 Photographic Studio

1.5.5 Personal Purchase

1.5.6 Others

1.6 Study Objectives

1.7 Years Considered

2 Global Growth Trends by Regions

2.1 Stem Cell Banking Market Perspective (2015-2026)

2.2 Stem Cell Banking Growth Trends by Regions

2.2.1 Stem Cell Banking Market Size by Regions: 2015 VS 2020 VS 2026

2.2.2 Stem Cell Banking Historic Market Share by Regions (2015-2020)

2.2.3 Stem Cell Banking Forecasted Market Size by Regions (2021-2026)

2.3 Industry Trends and Growth Strategy

2.3.1 Market Top Trends

2.3.2 Market Drivers

2.3.3 Market Challenges

2.3.4 Porters Five Forces Analysis

2.3.5 Stem Cell Banking Market Growth Strategy

2.3.6 Primary Interviews with Key Stem Cell Banking Players (Opinion Leaders)

3 Competition Landscape by Key Players

3.1 Global Top Stem Cell Banking Players by Market Size

3.1.1 Global Top Stem Cell Banking Players by Revenue (2015-2020)

3.1.2 Global Stem Cell Banking Revenue Market Share by Players (2015-2020)

3.1.3 Global Stem Cell Banking Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

3.2 Global Stem Cell Banking Market Concentration Ratio

3.2.1 Global Stem Cell Banking Market Concentration Ratio (CR5 and HHI)

3.2.2 Global Top 10 and Top 5 Companies by Stem Cell Banking Revenue in 2019

3.3 Stem Cell Banking Key Players Head office and Area Served

3.4 Key Players Stem Cell Banking Product Solution and Service

3.5 Date of Enter into Stem Cell Banking Market

3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

4.1 Global Stem Cell Banking Historic Market Size by Type (2015-2020)

4.2 Global Stem Cell Banking Forecasted Market Size by Type (2021-2026)

5 Stem Cell Banking Breakdown Data by Application (2015-2026)

5.1 Global Stem Cell Banking Market Size by Application (2015-2020)

5.2 Global Stem Cell Banking Forecasted Market Size by Application (2021-2026)

6 North America

6.1 North America Stem Cell Banking Market Size (2015-2020)

6.2 Stem Cell Banking Key Players in North America (2019-2020)

6.3 North America Stem Cell Banking Market Size by Type (2015-2020)

6.4 North America Stem Cell Banking Market Size by Application (2015-2020)

7 Europe

7.1 Europe Stem Cell Banking Market Size (2015-2020)

7.2 Stem Cell Banking Key Players in Europe (2019-2020)

7.3 Europe Stem Cell Banking Market Size by Type (2015-2020)

7.4 Europe Stem Cell Banking Market Size by Application (2015-2020)

8 China

8.1 China Stem Cell Banking Market Size (2015-2020)

8.2 Stem Cell Banking Key Players in China (2019-2020)

8.3 China Stem Cell Banking Market Size by Type (2015-2020)

8.4 China Stem Cell Banking Market Size by Application (2015-2020)

9 Japan

9.1 Japan Stem Cell Banking Market Size (2015-2020)

9.2 Stem Cell Banking Key Players in Japan (2019-2020)

9.3 Japan Stem Cell Banking Market Size by Type (2015-2020)

9.4 Japan Stem Cell Banking Market Size by Application (2015-2020)

10 Southeast Asia

10.1 Southeast Asia Stem Cell Banking Market Size (2015-2020)

10.2 Stem Cell Banking Key Players in Southeast Asia (2019-2020)

10.3 Southeast Asia Stem Cell Banking Market Size by Type (2015-2020)

10.4 Southeast Asia Stem Cell Banking Market Size by Application (2015-2020)

11 India

11.1 India Stem Cell Banking Market Size (2015-2020)

11.2 Stem Cell Banking Key Players in India (2019-2020)

11.3 India Stem Cell Banking Market Size by Type (2015-2020)

11.4 India Stem Cell Banking Market Size by Application (2015-2020)

12 Central & South America

12.1 Central & South America Stem Cell Banking Market Size (2015-2020)

12.2 Stem Cell Banking Key Players in Central & South America (2019-2020)

The rest is here:
Stem Cell Banking Market 2020 Global Trend, Segmentation and Opportunities, Forecast 2026 - 3rd Watch News

Deep Brain Stimulation Systems Market Growth, Scope, Future Trends, Industry Outlook: Post COVID Investors Eye Bigger-Than-Expected: Beijing PINS…

Deep Brain Stimulation Systems MarketBy Product Type (Single-Channel Deep Brain Stimulator, Dual-Channel Deep Brain Stimulator), Application (Obsessive Compulsive Disorder, Parkinsons Disease, Essential Tremor, Epilepsy, Dystonia), Type (Rechargeable, Non-Rechargeable), End-User (Hospitals, Ambulatory Surgical Centers (ASCs), Neurological Clinic), Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Market Trends and Forecast to 2027

The global deep brain stimulation systems market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 8.5% in the forecast period of 2020 to 2027and expected to reach USD 1,954.35 million by 2027 from USD 1,017.57 million in 2019. Rising demand for early and accurate disease diagnosis is the factor for market growth.

The major players covered in the report areNeuroPace, Inc, Boston Scientific Corporation, Fisher Wallace, SceneRayCorporation, Limited, Beijing PINS Medical Co., Ltd, ALEVA NEUROTHERAPEUTICS SA, MEDTRONIC, and Abbott among other players domestic and global.

Get Sample Copy of this Report(Avail 30% Discount Till Limited Period) @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-deep-brain-stimulation-systems-market

Market Analysis and Insights: Global Deep Brain Stimulation Systems Market

Deep brain stimulation systems is playing significant role to enable doctors to make appropriate clinical and diagnostic decisions across various levels of health care services. Increasing demand for diagnostic tests is augmenting the market growth as they are used for clinical diagnoses tests.

Deep brain stimulation systems demand has been increased with rising cases of neurological disorders as compared to the past few years will accelerate the market growth. For instance, in January 2019, Abbott announced that they have received CE mark approval for their Bluetooth-enabled software upgrades to all currently installed Infinity DBS systems which deliver MR-conditional labelling and innovative features. After receiving CE mark approval, the company commercialize and expand their business in the market

High cost of deep brain stimulation devices and surgery will hamper the deep brain stimulation systems market as which further creates new opportunities for deep brain stimulation systems with growing advancement in novel technologies. Such technology support Deep Brain Stimulation Systems market growth in the forecast period to 2027.

This deep brain stimulation systems market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for anAnalyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Cell and Gene Therapy Digital Conference

Cell and Gene Therapy Digital Conference| Register at:https://www.databridgemarketresearch.com/digital-conference/cell-and-gene-therapy

Global Deep Brain Stimulation Systems Market Scope and Market Size

Deep brain stimulation systems market is segmented on the basis of product type, application and type, end user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Explore Full Report With Detailed TOC Here @https://www.databridgemarketresearch.com/toc/?dbmr=global-deep-brain-stimulation-systems-market

Deep Brain Stimulation Systems Market Country Level Analysis

Deep brain stimulation systems market is analysed and market size information is provided by country by product type, application, type, end user type as referenced above.

The countries covered in the deep brain stimulation systems market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific in the Asia-Pacific, South Africa, Rest of Middle East and Africa as a part of Middle East and Africa, Brazil and Rest of South America as part of South America.

Country Level Analysis, By Product Type

North America dominates the deep brain stimulation Systems market as the U.S. is leader in deep brain stimulation systems. In North America due to better advancement in products and services, this region is dominating the deep brain stimulation systems. North America accounts higher healthcare expenditure, especially in U.S. Asia-Pacific is growing with the highest CAGR due to increase in medical tourism as well as increase in population. Numbers of companies in emerging countries are increasing due to increase in demand for neurology disease, hospitals and other areas. Additionally, the increasing number of healthcare expenditure and increasing number of hospitals and neurology clinics in China and India upsurge demand of deep brain stimulation systems. Asia-Pacific region is expected to grow with the highest growth rate in the forecast period of 2020 to 2027 because of increasing Parkinsons diseases among population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Huge Investment by Laboratory for Deep Brain Stimulation Systems and New Technology Penetration

Deep brain stimulation systems market also provides you with detailed market analysis for every country growth in life science industry with deep brain stimulation systems demand impact of technological development in laboratory services and changes in regulatory scenarios with their support for the deep brain stimulation systems market. The data is available for historic period 2010 to 2018.

Competitive Landscape and Deep Brain Stimulation Systems Market Share Analysis

Deep brain stimulation systems market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, concept cars, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companys focus related to global Deep Brain Stimulation Systems market.

Many Business Expansion and developments are also initiated by the companies worldwide which are also accelerating the global Deep Brain Stimulation Systems market.

For instance,

Partnership, joint ventures and other strategies enhances the company market share with increased coverage and presence. It also provides the benefit for organisation to improve their offering for deep brain stimulation systems through expanded model range.

Customization Available: Global Deep Brain Stimulation Systems Market

Data Bridge Market Researchis a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

Inquiry Before Buying @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-deep-brain-stimulation-systems-market

Continue reading here:
Deep Brain Stimulation Systems Market Growth, Scope, Future Trends, Industry Outlook: Post COVID Investors Eye Bigger-Than-Expected: Beijing PINS...

New report offers analysis on the Induced Pluripotent Stem Cells Market – Jewish Life News

This Induced Pluripotent Stem Cells Market report offers a detailed view of market opportunity by end user segments, product segments, sales channels, key countries, and import / export dynamics. It details market size & forecast, growth drivers, emerging trends, market opportunities, and investment risks in over various segments in Induced Pluripotent Stem Cells industry. It provides a comprehensive understanding of Induced Pluripotent Stem Cells market dynamics in both value and volume terms.

About Induced Pluripotent Stem Cells Industry

The overviews, SWOT analysis and strategies of each vendor in the Induced Pluripotent Stem Cells market provide understanding about the market forces and how those can be exploited to create future opportunities.

Important application areas of Induced Pluripotent Stem Cells are also assessed on the basis of their performance. Market predictions along with the statistical nuances presented in the report render an insightful view of the Induced Pluripotent Stem Cells market. The market study on Global Induced Pluripotent Stem Cells Market 2018 report studies present as well as future aspects of the Induced Pluripotent Stem Cells Market primarily based upon factors on which the companies participate in the market growth, key trends and segmentation analysis.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2635628&source=atm

The report firstly introduced the Induced Pluripotent Stem Cells basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

The major players profiled in this report include: BlueRock Therapeutics Corning Life Sciences EMD Millipore Lonza Group Promega Thermo Fisher Scientific

The end users/applications and product categories analysis: On the basis of product, this report displays the sales volume, revenue (Million USD), product price, market share and growth rate of each type, primarily split into- General Type

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Induced Pluripotent Stem Cells for each application, including- Medical

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2635628&source=atm

The scope of Induced Pluripotent Stem Cells Market report:

Global market size, supply, demand, consumption, price, import, export, macroeconomic analysis, type and application segment information by region, including:

Global (Asia-Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia]

Europe [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]

North America [United States, Canada, Mexico]

Middle East & Africa [GCC, North Africa, South Africa],

South America [Brazil, Argentina, Columbia, Chile, Peru])

Industry chain analysis, raw material and end users information

Global key players information including SWOT analysis, companys financial figures, Laser Marking Machine figures of each company are covered.

Powerful market analysis tools used in the report include: Porters five forces analysis, PEST analysis, drivers and restraints, opportunities and threatens.

Based year in this report is 2019; the historical data is from 2014 to 2018 and forecast year is from 2020 to 2024.

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2635628&licType=S&source=atm

Manufacturing Analysis Induced Pluripotent Stem Cells Market

Manufacturing process for the Induced Pluripotent Stem Cells is studied in this section. It includes through analysis of Key Raw Materials, Key Suppliers of Raw Materials, Price Trend of Key Raw Materials, cost of Raw Materials & Labor Cost, Manufacturing Process Analysis of Induced Pluripotent Stem Cells market

Marketing Strategy Analysis, Distributors/Traders Analysis of Induced Pluripotent Stem Cells Market

Various marketing channels like direct and indirect marketing are portrayed in Induced Pluripotent Stem Cells market report. Important marketing strategical data , Marketing Channel Development Trend, , Pricing Strategy, Market Positioning, Target Client Brand Strategy and Distributors/Traders List

See the original post:
New report offers analysis on the Induced Pluripotent Stem Cells Market - Jewish Life News